mRNA vaccine designs for optimal adjuvanticity and delivery
Adjuvanticity and delivery are crucial facets of mRNA vaccine design. In modern mRNA vaccines, adjuvant functions are integrated into mRNA vaccine nanoparticles, allowing the co-delivery of antigen mRNA and adjuvants in a unified, all-in-one formulation. In this formulation, many mRNA vaccines utili...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | RNA Biology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15476286.2024.2333123 |
| _version_ | 1826937955055304704 |
|---|---|
| author | Yuki Mochida Satoshi Uchida |
| author_facet | Yuki Mochida Satoshi Uchida |
| author_sort | Yuki Mochida |
| collection | DOAJ |
| description | Adjuvanticity and delivery are crucial facets of mRNA vaccine design. In modern mRNA vaccines, adjuvant functions are integrated into mRNA vaccine nanoparticles, allowing the co-delivery of antigen mRNA and adjuvants in a unified, all-in-one formulation. In this formulation, many mRNA vaccines utilize the immunostimulating properties of mRNA and vaccine carrier components, including lipids and polymers, as adjuvants. However, careful design is necessary, as excessive adjuvanticity and activation of improper innate immune signalling can conversely hinder vaccination efficacy and trigger adverse effects. mRNA vaccines also require delivery systems to achieve antigen expression in antigen-presenting cells (APCs) within lymphoid organs. Some vaccines directly target APCs in the lymphoid organs, while others rely on APCs migration to the draining lymph nodes after taking up mRNA vaccines. This review explores the current mechanistic understanding of these processes and the ongoing efforts to improve vaccine safety and efficacy based on this understanding. |
| first_indexed | 2024-04-24T19:16:11Z |
| format | Article |
| id | doaj.art-484502ec6d7f4372b2fd86b2d8fd6a78 |
| institution | Directory Open Access Journal |
| issn | 1547-6286 1555-8584 |
| language | English |
| last_indexed | 2025-02-17T18:48:52Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | RNA Biology |
| spelling | doaj.art-484502ec6d7f4372b2fd86b2d8fd6a782024-12-11T07:15:42ZengTaylor & Francis GroupRNA Biology1547-62861555-85842024-12-0121142244810.1080/15476286.2024.2333123mRNA vaccine designs for optimal adjuvanticity and deliveryYuki Mochida0Satoshi Uchida1Department of Advanced Nanomedical Engineering, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, JapanDepartment of Advanced Nanomedical Engineering, Medical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, JapanAdjuvanticity and delivery are crucial facets of mRNA vaccine design. In modern mRNA vaccines, adjuvant functions are integrated into mRNA vaccine nanoparticles, allowing the co-delivery of antigen mRNA and adjuvants in a unified, all-in-one formulation. In this formulation, many mRNA vaccines utilize the immunostimulating properties of mRNA and vaccine carrier components, including lipids and polymers, as adjuvants. However, careful design is necessary, as excessive adjuvanticity and activation of improper innate immune signalling can conversely hinder vaccination efficacy and trigger adverse effects. mRNA vaccines also require delivery systems to achieve antigen expression in antigen-presenting cells (APCs) within lymphoid organs. Some vaccines directly target APCs in the lymphoid organs, while others rely on APCs migration to the draining lymph nodes after taking up mRNA vaccines. This review explores the current mechanistic understanding of these processes and the ongoing efforts to improve vaccine safety and efficacy based on this understanding.https://www.tandfonline.com/doi/10.1080/15476286.2024.2333123mRNA vaccineadjuvantinnate immunitymRNA deliverylipid nanoparticlepolyplex |
| spellingShingle | Yuki Mochida Satoshi Uchida mRNA vaccine designs for optimal adjuvanticity and delivery RNA Biology mRNA vaccine adjuvant innate immunity mRNA delivery lipid nanoparticle polyplex |
| title | mRNA vaccine designs for optimal adjuvanticity and delivery |
| title_full | mRNA vaccine designs for optimal adjuvanticity and delivery |
| title_fullStr | mRNA vaccine designs for optimal adjuvanticity and delivery |
| title_full_unstemmed | mRNA vaccine designs for optimal adjuvanticity and delivery |
| title_short | mRNA vaccine designs for optimal adjuvanticity and delivery |
| title_sort | mrna vaccine designs for optimal adjuvanticity and delivery |
| topic | mRNA vaccine adjuvant innate immunity mRNA delivery lipid nanoparticle polyplex |
| url | https://www.tandfonline.com/doi/10.1080/15476286.2024.2333123 |
| work_keys_str_mv | AT yukimochida mrnavaccinedesignsforoptimaladjuvanticityanddelivery AT satoshiuchida mrnavaccinedesignsforoptimaladjuvanticityanddelivery |